| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | BRISTOL MYERS SQUIBB CO | 150,000 | 7,677,000 | 1.58% | ||
| 52 | DEXCOM INC | 200,000 | 7,998,000 | 1.65% | ||
| 53 | TESARO INCORPORATED | 300,000 | 8,076,000 | 1.66% | ||
| 54 | OVASCIENCE INC COM | 516,200 | 8,569,000 | 1.76% | ||
| 55 | AKEBIA THERAPEUTICS INC | 400,000 | 8,852,000 | 1.82% | ||
| 56 | BIOCRYST PHARMACEUTICALS | 1,100,000 | 10,758,000 | 2.21% | ||
| 57 | ACCELERON PHARMA INC | 400,000 | 12,096,000 | 2.49% | ||
| 58 | Arrowhead Pharma Inc | 900,000 | 13,293,000 | 2.73% | ||
| 59 | NEUROCRINE BIOSCIE COM USD0.001 | 850,000 | 13,320,000 | 2.74% | ||
| 60 | KARYOPHARM THERAPEUTICS INC COM | 385,000 | 13,452,000 | 2.77% | ||
| 61 | KERYX BIOPHARMACEUTICALS INCORPORATED | 1,000,000 | 13,750,000 | 2.83% | ||
| 62 | DYAX CORP COM CVR | 1,500,000 | 15,180,000 | 3.12% | ||
| 63 | JAZZ PHARMACEUTICALS PLC | 100,000 | 16,056,000 | 3.30% | ||
| 64 | Receptos Inc | 748,700 | 46,502,000 | 9.56% | ||
| 65 | PUMA BIOTECHNOLOGY | 507,500 | 121,074,000 | 24.90% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-14-041889, filed 2014.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
